Next Article in Journal
An Updated Cost-Utility Model for Onasemnogene Abeparvovec (Zolgensma®) in Spinal Muscular Atrophy Type 1 Patients and Comparison with Evaluation by the Institute for Clinical and Effectiveness Review (ICER)
Previous Article in Journal
A Conceptual Framework to Develop a Patient-Reported Experience Measure of the Quality of Mental Health Care: A Qualitative Study of the PREMIUM Project in France
 
 
Article

No Article Versions Notes Found

Back to TopTop